Table 3 Characteristic of patients with HBV reactivation
Cases = 16 | % | |
|---|---|---|
Pretreatment | ||
Age (years) | ||
Mean ± SD | 48 ± 4 | |
Range | 41–55 | |
Sex | ||
Female | 3 | 18.8% |
Male | 13 | 81.3% |
Fibrosis stage by Fibroscan | ||
F0 | 7 | 43.8% |
F1 | 5 | 31.3% |
F2 | 4 | 25.0% |
AST(IU/L) | ||
Mean ± SD | 42 ± 14 | |
Range | 27–75 | |
ALT(IU/L) | ||
Mean ± SD | 40 ± 13 | |
Range | 28–77 | |
DAAs | ||
SOF + Ledipasvir | 3 | 18.8% |
SOF + DAC | 13 | 81.2% |
HCV RNA (× 105) | ||
Mean ± SD | 4.1 ± 0.95 | |
Range | 2.4–6.3 | |
HCV SVR12 | ||
Yes | 16 | 100.0% |
AT HBV reactivation | ||
Type of NUC | ||
ETV | 8 | 50.0% |
TDF | 8 | 50.0% |
ALT (IU/L) | ||
Mean ± SD | 84 ± 8 | |
Range | 72–103 | |
Total bilirubin (mg/dL) | ||
Mean ± SD | 1.03 ± 0.3 | |
Range | 0.6–1.6 | |
HBV DNA (× 103) (IU/mL) | ||
Mean ± SD | 3.59 ± 1.04 | |
Range | 2.3–5.8 | |
Outcome | ||
Flare | ||
No flare | 16 | 100.0% |
Recovery | ||
Recovery in 3 months | 16 | 100.0% |
Death | ||
No death | 16 | 100.0% |